TB Biosciences Raises $1.5M in Series A Financing | GenomeWeb

NEW YORK (GenomeWeb News) – TB Biosciences, which is developing a point-of-care test for the detection of tuberculosis, said today it has closed on its Series A financing round, raising $1.5 million.

The financing will be used to support product development and clinical trials.

Originate Ventures led the round, which also included investors Ben Franklin Technology Partners of Northeastern Pennsylvania and the NYU Innovation Venture Fund. With recent funding from the National Institutes of Health, new funds total $2.5 million, the Bethlehem, Penn.-based company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: transcriptional and translational study of human cytomegalovirus interactions with host cells, spider web DNA study, and more.

The New York Stem Cell Foundation signs a lease for a new space.

Researchers gear up for an international meeting to discuss the ethics of gene editing.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.